An open-label, multicenter, phase II study of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for salvage therapy in patients with HER2-expressing advanced solid tumors(PRaG3.0).

Who was studied?

8 enrolled patients; 6 had at least one tumor assessment.

What does the publication report?

Among 6 assessed patients, ORR was 66.7% and DCR 83.3%.

Safety findings

No grade ≥3 adverse events were reported in the early cohort.

How should we interpret it?

Conference-level, non-randomized evidence. Linked reports may include the same participants and should not be counted as independent trials.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

An open-label, multicenter, phase II study of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for salvage therapy in patients with HER2-expressing advanced solid tumors(PRaG3.0). · DOI: 10.1200/JCO.2022.40.16_suppl.e14565

• Official publication source ↗
• Publisher via DOI ↗

Related publications from the same research program

• Case Report: PRaG 3.0 therapy for advanced cervical cancer with severe comorbidities
• Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol)
• A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors.

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.